Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort

Giulia Tueur^{1

2}, Gregory Lazarian^{1

3

4}, Virginie Eclache^{1

3

4}, Carole Fleury^{1

3

4}, Rémi Letestu^{1

3

4}, Vincent Lévy⁵, Valérie Lefebvre¹, Jean-Francois Collon¹, Jean-Marc Zini⁶, Catherine Thieblemont⁶, Thierry Soussi^{7

8

9}, Florence Cymbalista^{1

3

4}, Fanny Baran-Marszak^{1

3

4}

Affiliations

¹ Laboratoire d'hématologie, Hôpital Avicenne, AP-HP, Bobigny, France.
² Laboratoire d'hématologie, Hôpital Saint-Louis, AP-HP, Paris, France.
³ Université Paris 13, Paris Sorbonne Université, Bobigny, France.
⁴ U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.
⁵ Unité de Recherche Clinique/Centre de Recherche Clinique, Hôpital Avicenne, APHP, Bobigny, France.
⁶ Service d'onco-hématologie, APHP, Hôpital Saint-Louis, Paris, France.
⁷ INSERM UMR 1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, Paris, France.
⁸ Sorbonne Université, UPMC Université Paris 06, Paris, France.
⁹ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Giulia Tueur et al. Br J Haematol. 2020 Nov.

. 2020 Nov;191(3):e90-e94.

doi: 10.1111/bjh.17046. Epub 2020 Aug 13.

¹ Laboratoire d'hématologie, Hôpital Avicenne, AP-HP, Bobigny, France.
² Laboratoire d'hématologie, Hôpital Saint-Louis, AP-HP, Paris, France.
³ Université Paris 13, Paris Sorbonne Université, Bobigny, France.
⁴ U978 Institut National de la Santé et de la Recherche Médicale, Bobigny, France.
⁵ Unité de Recherche Clinique/Centre de Recherche Clinique, Hôpital Avicenne, APHP, Bobigny, France.
⁶ Service d'onco-hématologie, APHP, Hôpital Saint-Louis, Paris, France.
⁷ INSERM UMR 1138, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, Paris, France.
⁸ Sorbonne Université, UPMC Université Paris 06, Paris, France.
⁹ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

No abstract available

Keywords: NGS; TP53 mutation; XPO1 mutation; chronic lymphocytic leukemia.

References

1. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525-30.
1. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519-24.
1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-60.
1. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-54.
1. Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031-42.